NCT00217503View on ClinicalTrials.gov

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Study Completion Date

June 30, 2007

Conditions

Lymphoma

Interventions

BIOLOGICAL

bevacizumab

BIOLOGICAL

filgrastim

BIOLOGICAL

pegfilgrastim

DRUG

bortezomib

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

ganciclovir

DRUG

valganciclovir

DRUG

zidovudine

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00217503 - Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma | Biotech Hunter | Biotech Hunter